Gland Pharma Q2 FY27 Revenue Up 23%, PAT Up 58%

Gland Pharma Limited announced its financial results for the second quarter ended September 30th, 2026, reporting a strong performance with revenue growth of 23% year-on-year to ₹18,336 million and profit after tax (PAT) increasing by 58% year-on-year to ₹2,908 million. The company's CDMO business saw a significant 31% year-on-year growth, contributing 45% of total revenues, while the Critical Injectables business grew by 18%, accounting for 55% of revenues. Adjusted EBITDA also saw a substantial increase of 50% year-on-year, reaching ₹5,030 million, with an improved margin of 27%. R&D investments stood at ₹1,077 million, representing 6% of consolidated revenue. The US market was a key driver of growth, with revenues increasing by 42% year-on-year.